News for LivaNova PLC (LIVN)

We recently compiled a list of the 7 Best Medical Technology Stocks To Buy According To Analysts. In this article, we are going to take a look at where LivaNova PLC (NASDAQ:LIVN) stands against the other...

Robust growth in Cardiopulmonary and Neuromodulation segments, with net revenue increases of 13.1% and 6.6% respectively.Effective management of supply chain d

Organic Revenue Growth (2024): 11% for the full year.Revenue Growth (Q4 2024): 5% overall, 7% organic growth compared to Q4 2023.Adjusted Operating Income Grow

Feb 25, 2025 / 01:00PM GMTOperator Good day ladies and gentlemen, and welcome to the LivaNova PLC fourth quarter and full year 2024 and this conference call. As

LivaNova PLC (NASDAQ:LIVN) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ETCompany ParticipantsBriana Gotlin - Vice President, Investor...

LivaNova (LIVN) delivered earnings and revenue surprises of 1.25% and 0.48%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2024 results and issued full-year 2025 gu

Revenue: Fourth-quarter revenue reached $321.8 million, slightly below the estimated $324.06 million, marking a 3.8% increase year-over-year.Earnings Per Share

Shares of LivaNova PLC (LIVN) surged 4.34% in mid-day trading on Feb 25. The stock reached an intraday high of $49.80, before settling at $49.52, up from it

Summary LivaNova PLC (LIVN), a leading medical technology company, announced that its CEO, Vladimir Makatsaria, will participate in a fireside chat at the Barcl

LivaNova PLC (LIVN), a prominent medical technology company, has announced it will host a conference call to discuss its fourth-quarter and full-year 2024 finan

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2024 results

LivaNova PLC (LIVN), a leading medical technology company, announced the appointment of Natalia Kozmina as Chief Human Resources Officer (CHRO), effective Janua

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources

On December 11, 2024, Francesco Bianchi, a Director at LivaNova PLC, sold 1,250 shares of the company. Following this transaction, the insider now owns 7,522 sh

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its participation in the American Epilepsy Society (AES) 2024 Annual

Shares of LivaNova PLC (LIVN) surged 3.53% in mid-day trading on Nov 28. The stock reached an intraday high of $52.66, before settling at $52.48, up from it

The mean of analysts' price targets for LivaNova (LIVN) points to a 37.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The Perfusion Systems Market Size sector reached a market value of USD 4.62 billion in 2023. Future projections show a bright outlook, with a Compound Annual Growth Rate (CAGR) of 11% from 2023 to…